DV
Dividend Vision

VRDN — Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. (VRDN)

Total return is -98.9% over the past 12.2 years, 485.0 points behind SPY at 386.1%. Its deepest 1-year drawdown was 60.6%.

Viridian Therapeutics, Inc. is a biopharmaceutical company discovering, developing, and commercializing treatments for serious and rare diseases, with a focus on thyroid eye disease and Graves' disease through IGF-1R targeted therapies and other immunological approaches. The company does not currently distribute dividends. Viridian appeals to investors focused on growth potential in the specialty pharmaceutical and rare disease treatment sectors rather than income generation.

VRDN key facts

Asset type
Stock
Asset class
Equity
Inception date
06/18/2014
Last close
$22.08
Market cap
$2,501,493,248
Average volume
1093300.0
Payment date
11/13/2020
Beta
0.94
Payout ratio
0.0
Forward P/E
1.0072
EPS
$-3.42